Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179843 | 0.85 | ALOX15 (1.00) | ALOX15SIGMAR1ACE2ALDH1A1 | |
| SCHEMBL384210 | 0.85 | DRD2 (0.52) | ALOX15DRD2SIGMAR1GNAI3GNAO1 | |
| SCHEMBL6512381 | 0.85 | DRD2 (0.52) | ALOX15DRD2SIGMAR1GNAI3GNAO1 | |
| SCHEMBL19546253 | 0.85 | DRD2 (0.52) | ALOX15DRD2SIGMAR1GNAI3GNAO1 | |
| SCHEMBL681521 | 0.85 | — | — | |
| SCHEMBL1046369 | 0.85 | DRD2 (0.52) | ALOX15DRD2SIGMAR1GNAI3GNAO1 | |
| SCHEMBL3975418 | 0.85 | ALOX15 (1.00) | ALOX15SIGMAR1ACE2ALDH1A1 | |
| SCHEMBL242967 | 0.85 | — | — | |
| SCHEMBL4392829 | 0.84 | ALOX15 (0.65) | ALOX15SIGMAR1ACE2GNAI3GNAO1 | |
| SCHEMBL1861653 | 0.84 | KEAP1 (0.54) | ALOX15SIGMAR1ACE2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-2365962-B1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170119907-A1 | Targeted Therapeutics | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9631131-B2 | Polyaminopolyamide-epichlorohydrin resins for use as clay and shale inhibition agents for the drilling industry | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-3097908-A1 | LIPID COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2016-11-30 | — | — | EP | disclosed |
| US-20150353807-A1 | POLYAMINOPOLYAMIDE-EPICHLOROHYDRIN RESINS FOR USE AS CLAY AND SHALE INHIBITION AGENTS FOR THE DRILLING INDUSTRY | THE DOW CHEMICAL COMPANY (US) | 2015-12-10 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906979-B2 | Macrophotoinitiators | BASF SE (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| US-5326870-A | Asthma; bronchodilator agents; respiratory system disorders | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0525203-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVE OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | ALOX15 4810/4885DRD2 4732/4885SIGMAR1 2720/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | ALOX15 2471/4885DRD2 4829/4885SIGMAR1 4266/4885 |
| US-20170119907-A1 | Targeted Therapeutics | ANXA3, ANXA5, ANXA6 | ALOX15 2768/4885DRD2 3840/4885SIGMAR1 2054/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | ALOX15 4836/4885DRD2 4657/4885SIGMAR1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.